Werewolf Therapeutics
Operates as an oncology biotherapeutics company.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $50.0m | POST IPO SECONDARY |
| Total Funding | 000k | ||
DC Capital Partners(exited)
MPM BioImpact(exited)
Taiho Pharma(exited)
Taiho Ventures(exited)
Arkin Holdings(exited)
RA Capital Management(exited)
UPMC Enterprises(exited)
Deerfield Capital Management(exited)
HBM Healthcare Investments(exited)
Soleus Capital(exited)
Adage Capital(exited)
HBM Partners(exited)
DC Investment Partners(exited)
BioImpact Capital(exited)
Longwood Fund(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 22 % | (91 %) | - | - | (54 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (342 %) | (163 %) | (3368 %) | - | (781 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (328 %) | (187 %) | (3741 %) | - | (975 %) | (3190 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 328 % | 209 % | 2994 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.